EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

The Impact of SGLT2 Inhibitors on Pulmonary Artery Pressures and Pulmonary Hemodynamics in Patients With Heart Failure: A Systematic Review

Kritick Bhandari iD, Maria Qadri iD, Rochak Dhakal, Sagun Ghimire iD, Gyanendra Jora iD, Santosh Basyal iD, Sanjit Kumar Shah iD

Cardiovascular Therapeutics · 2025

DOI: 10.1155/cdr/6649731 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cardiovascular Therapeutics, 2025. Verfasst von Kritick Bhandari und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, KIST Medical College and Teaching Hospital, Lalitpur, Bagmati, Nepal. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Pulmonary Artery, Arterial Pressure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Heart failure is a major global health burden associated with high morbidity and mortality. Elevated pulmonary artery pressures (PAP) are linked to worse outcomes in heart failure patients. Sodium–glucose cotransporter 2 (SGLT2) inhibitors, initially developed for diabetes, have demonstrated cardiovascular benefits, but their specific effects on pulmonary hemodynamics remain unclear.

Methods

This systematic review analyzed randomized controlled trials and observational cohort studies evaluating the effects of SGLT2 inhibitors on mean pulmonary artery pressure (mPAP) and pulmonary artery systolic pressure (PASP) in heart failure patients. A comprehensive search of PubMed, Embase, Cochrane Library, and Scopus databases was conducted until August 2024. Studies were appraised using PRISMA and AMSTAR guidelines, the Cochrane bias tool, and the Newcastle–Ottawa Scale. Hypothesis SGLT2 inhibitors reduce PAPs in heart failure patients, leading to beneficial pulmonary hemodynamic effects.

Results

Six studies (four RCTs and two observational; n = 346) were included. At rest, pooled analysis of three trials showed a significant reduction in mPAP (MD −1.41 mmHg; 95% CI −2.80 to −0.01; p = 0.05; I 2 = 12 % ). During exercise, two studies demonstrated a nonsignificant reduction in mPAP (MD −3.12 mmHg; 95% CI −7.60 to 1.36; p = 0.17; I 2 = 54 % ). For PASP, pooled analysis of four studies suggested a nonsignificant reduction (MD −6.72 mmHg; 95% CI −14.98 to 1.54; p = 0.11; I 2 = 96 % ), but sensitivity analysis excluding one outlier yielded a significant effect (MD −2.76 mmHg; 95% CI −4.99 to −0.53; p = 0.02; I 2 = 0 % ). Secondary outcomes included significant reductions in PCWP, PADP, and NT‐proBNP.

Conclusion

SGLT2 inhibitors demonstrate beneficial effects on pulmonary pressures and hemodynamics in patients with heart failure, with consistent trends toward lower mPAP, PASP, and PCWP. Although results are influenced by study heterogeneity, the overall evidence suggests meaningful hemodynamic improvements. Larger, long‐term randomized trials are warranted to clarify subgroup effects (HFrEF vs. HFpEF and dapagliflozin vs. empagliflozin) and establish clinical implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsHeart FailurePulmonary ArteryArterial PressureHumansTreatment OutcomeRandomized Controlled Trials as TopicObservational Studies as TopicMaleFemaleAgedMiddle AgedHemodynamics

Stichwörter der Autor:innen

SGLT2 inhibitorsheart failureheart failure with preserved ejection fractionheart failure with reduced ejection fractionpulmonary artery pressurespulmonary hemodynamicspulmonary hypertension

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, KIST Medical College and Teaching Hospital, Lalitpur, Bagmati, Nepal.
  • Department of Internal Medicine, Jinnah Sindh Medical University, Karachi, Sindh, Pakistan.
  • Department of Applied Computing, Michigan Technological University, Houghton, Michigan, USA.
  • Department of Internal Medicine, Nepal Medical College, Kathmandu, Bagmati, Nepal.

ORCID-Profile: Kritick Bhandari, Maria Qadri, Sagun Ghimire, Gyanendra Jora, Santosh Basyal, Sanjit Kumar Shah

Zitieren

APA

Bhandari, K., Qadri, M., Dhakal, R., Ghimire, S., Jora, G., Basyal, S., & Shah, S. K. (2025). The Impact of SGLT2 Inhibitors on Pulmonary Artery Pressures and Pulmonary Hemodynamics in Patients With Heart Failure: A Systematic Review. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/6649731

Vancouver

Bhandari K, Qadri M, Dhakal R, Ghimire S, Jora G, Basyal S, et al. The Impact of SGLT2 Inhibitors on Pulmonary Artery Pressures and Pulmonary Hemodynamics in Patients With Heart Failure: A Systematic Review. Cardiovascular Therapeutics. 2025. doi:10.1155/cdr/6649731

BibTeX
@article{Bhandari2025,
  author = {Bhandari, Kritick and Qadri, Maria and Dhakal, Rochak and Ghimire, Sagun and Jora, Gyanendra and Basyal, Santosh and Shah, Sanjit Kumar},
  title = {The Impact of SGLT2 Inhibitors on Pulmonary Artery Pressures and Pulmonary Hemodynamics in Patients With Heart Failure: A Systematic Review},
  journal = {Cardiovascular Therapeutics},
  year = {2025},
  doi = {10.1155/cdr/6649731}
}
Kostenlos starten →